BenevolentAI: Data from Eli Lilly’s COV-BARRIER trial shows baricitinib reduced deaths in hospitalised COVID-19 patients by 38%
- The latest data published in Eli Lilly’s Phase 3 randomised, double-blind, placebo-controlled study (COV-BARRIER) shows the largest clinical effect reported to date for a reduction in mortality in the COVID-19 patient population
- Early in the pandemic, BenevolentAI researchers identified Baricitinib as a potential treatment for COVID-19 and published the hypothesis in The Lancet on February 4, 2020
- Data from the ACTT-2 clinical trial resulted in the FDA granting emergency use authorisation for baricitinib in combination with remdesivir to treat hospitalised COVID-19 patients by November 2020
LONDON, April 8, 2021 /PRNewswire/ — BenevolentAI, a leader in the application of AI and machine learning in drug discovery and development, congratulate Eli Lilly on results from its COV-BARRIER trial in 1,525 hospitalised COVID-19 patients demonstrating baricitinib reduces mortality by 38% (nominal p-value=0.0018), showing the largest clinical effect reported to date for a reduction in mortality in this patient population.
The COV-BARRIER results further validate BenevolentAI’s AI-derived hypothesis, first published in early February 2020, which prompted additional global trials and investigations into its efficacy as a treatment for critically ill COVID-19 patients. In the COV-BARRIER study, baricitinib was given in addition to the standard of care, which included dexamethasone in the majority of patients. The trial did not meet statistical significance on the primary endpoint, defined as a difference in the proportion of participants progressing to the first occurrence of non-invasive ventilation including high flow oxygen or invasive mechanical ventilation including extracorporeal membrane oxygenation (ECMO) or death by Day 28.
The significant reduction in mortality demonstrated in the COV-BARRIER trial follows several published studies confirming baricitnib’s therapeutic effect, such as those in EMBO Mol Med, Science Advances, J. Clin. Invest, New England Journal of Medicine, The Lancet Infectious Diseases and more. The results from the ACTT-2 clinical trial led to baricitinib being granted FDA emergency use authorisation in November, making it the first AI-derived hypothesis for a COVID-19 treatment validated in a large international randomised trial that received Emergency Use Authorisation in this unprecedented timeframe.
Baricitinib is approved for the treatment of rheumatoid arthritis and other diseases. It is administered orally and additional research is ongoing to further evaluate the potential role of baricitinib in COVID-19, including NIAID’s ACTT-4 trial (assessing the efficacy and safety of baricitinib or dexamethasone in combination with remdesivir in hospitalised adults with COVID-19 on supplemental oxygen), the UK’s RECOVERY trial and several investigator-initiated trials.
Media enquiries
Rajin Kang
rajin.kang@benevolent.ai
+447717 832 880
About BenevolentAI (www.benevolent.com)
BenevolentAI creates and applies AI and machine learning to transform the way medicines are discovered and developed, integrating its technology into every step of the drug discovery process, from hypothesis generation to early-stage clinical development. Benevolent has active in-house R&D drug programmes in disease areas such as neurodegeneration, immunology, oncology and inflammation and has research and commercial collaborations with leading pharmaceutical and research organisations. The company is headquartered in London with a research facility in Cambridge (UK) and a further office in New York.
View original content:http://www.prnewswire.com/news-releases/benevolentai-data-from-eli-lillys-cov-barrier-trial-shows-baricitinib-reduced-deaths-in-hospitalised-covid-19-patients-by-38-301265356.html
SOURCE BenevolentAI
